Is Glaukos (GKOS) overvalued or fairly valued?

MarketChacha shows Glaukos's valuation in context — a forward P/E of about 334.2, a price-to-book of about 15.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Glaukos's revenue?

Glaukos reported revenue of $507.4M for FY2025, with net profit of $-187.7M, per official filings.

What is the share price of Glaukos (GKOS)?

Glaukos last traded at $175.03 (+4.8% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Glaukos

GKOS · NYSE · Healthcare · United States

Snapshot

TickerGKOS

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees1,094

HeadquartersAliso Viejo, United States

Websitewww.glaukos.com

Filings tracked17

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Who owns it

Insiders3.6%
Institutions96.4%
Public & other0.0%

516 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.17%
Jupiter Topco LLC8.24%
Vanguard Portfolio Management LLC5.63%
Primecap Management Company5.16%
Vanguard Capital Management LLC4.33%
State Street Corporation3.93%
Millennium Management Llc2.68%
Holocene Advisors, LP2.57%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of -28.6% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-42.8% → -37.0%

Margin has expanded by about 5.8 points — the business is getting more profitable.

Return on equity-28.6%

Latest ROE of -28.6% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $187.5M · EPS 0.11

Est. earnings growth +138.3%

Next fiscal year

Rev $852.4M · EPS 0.52

Est. earnings growth +275.7%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$507.4M

Net margin

-37.0%

ROE

-28.6%

Revenue CAGR (2y)

+27.0%

EPS (FY2025)

-3.28

Net profit (FY2025)

$-187.7M

Ask MarketChacha about GKOS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$507.4M	$-187.7M	-3.28	-37.0%	-28.6%
FY2024	$383.5M	$-146.4M	-2.77	-38.2%	-19.1%
FY2023	$314.7M	$-134.7M	-2.78	-42.8%	-29.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$185.6M	$-18.4M	-0.31	-9.9%
2026Q1	$150.6M	$-19.8M	-0.34	-13.1%
2025Q3	$133.5M	$-16.2M	-0.28	-12.2%
2025Q2	$124.1M	$-19.7M	-0.34	-15.8%
2025Q1	$106.7M	$-18.1M	-0.32	-17.0%
2024Q3	$96.7M	$-21.4M	-0.39	-22.1%
2024Q2	$95.7M	$-50.5M	-1.00	-52.8%
2024Q1	$85.6M	$-40.8M	-0.82	-47.7%
2023Q3	$78.0M	$-30.4M	-0.63	-39.0%
2023Q2	$80.4M	$-32.8M	-0.68	-40.8%
2023Q1	$73.9M	$-34.6M	-0.72	-46.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Reg FD disclosure, Exhibits
SEC8/3/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/29/2026material
10-Q filing
SEC7/29/2026
8-K — Shareholder vote results
SEC6/3/2026material
8-K — Reg FD disclosure, Exhibits
SEC5/4/2026material
10-Q filing
SEC4/30/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC4/29/2026material
8-K — Reg FD disclosure, Exhibits
SEC3/2/2026material
10-K filing
SEC2/23/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/17/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/13/2026material

2025

8-K — Reg FD disclosure, Exhibits
SEC11/10/2025material
10-Q filing
SEC10/31/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC10/29/2025material
8-K — Reg FD disclosure, Exhibits
SEC8/12/2025material
10-Q filing
SEC8/4/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/30/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.